Hong Kong Tech Hardware Stock News

SEHK:3866
SEHK:3866Banks

Bank of Qingdao (SEHK:3866) Is Up 7.7% After Stronger 2025 Earnings - Has The Bull Case Changed?

Bank of Qingdao Co., Ltd. has reported full-year 2025 results, with net income rising to CNY 5,187.74 million and basic earnings per share from continuing operations reaching CNY 0.85, both up from the prior year. This earnings improvement highlights stronger profitability and may prompt investors to reassess the bank’s earnings power and operational efficiency. We will now examine how this stronger full-year profit performance shapes Bank of Qingdao’s investment narrative and future...
SEHK:1928
SEHK:1928Hospitality

Assessing Sands China (SEHK:1928) Valuation After Recent Share Price Weakness

Why Sands China is on investors’ radar Sands China (SEHK:1928) has drawn attention after recent share price weakness, with the stock showing negative returns over the past month, past 3 months and year, prompting closer scrutiny of its fundamentals. See our latest analysis for Sands China. With the share price at HK$17.03, Sands China has seen weaker momentum recently, with a 7 day share price return of 9.22% and a 30 day share price return of 14.76%, while the 1 year total shareholder return...
SEHK:753
SEHK:753Airlines

Assessing Air China (SEHK:753) Valuation After Guiding To A Substantial 2025 Net Loss

Air China (SEHK:753) has issued 2025 earnings guidance that points to a net loss of about CN¥1.3b to CN¥1.9b, which raises fresh questions about how quickly its profitability can stabilise. See our latest analysis for Air China. The earnings warning comes after a mixed share price run, with a 90 day share price return of 17.51% but a year to date share price return showing a 1.83% decline. At the same time, the 1 year total shareholder return of 46.33% indicates that longer term holders have...
SEHK:9969
SEHK:9969Biotechs

A Look At InnoCare Pharma (SEHK:9969) Valuation As It Targets First Profit On 2025 Revenue Growth

InnoCare Pharma (SEHK:9969) is back in focus after the company projected an improvement in its 2025 financial performance, supported by stronger drug sales and an anticipated move into profitability for the first time. See our latest analysis for InnoCare Pharma. That profit outlook comes after a mixed share price run, with the latest close at HK$11.72. The 1 year total shareholder return of 111.93% contrasts with a 5 year total shareholder return decline of 44.06%. This suggests recent...
SEHK:9863
SEHK:9863Auto

A Look At Leapmotor (SEHK:9863) Valuation After Clarifying Independent Domestic Share Subscription

Zhejiang Leapmotor Technology (SEHK:9863) has detailed a domestic share subscription under its general mandate, highlighting state owned Jinyi High-Tech as an independent, non connected investor and stressing compliance with Hong Kong listing rules. See our latest analysis for Zhejiang Leapmotor Technology. At a latest share price of HK$42.42, Zhejiang Leapmotor Technology’s short term share price returns, including a 30 day share price return of a 14.41% decline and a 90 day share price...
SEHK:1729
SEHK:1729Electrical

Assessing Time Interconnect Technology (SEHK:1729) Valuation After New Board And MedTech Leadership Appointments

Time Interconnect Technology (SEHK:1729) has reshaped its leadership with three new board appointments, bringing its Chief Operating Officer, its Executive Vice President for MedTech, and a healthcare academic leader formally into director roles. See our latest analysis for Time Interconnect Technology. The leadership reshuffle comes after a period of mixed share price momentum, with a 1 day share price return of 4.59% from a last close of HK$15.5, set against a 30 day share price return of...
SEHK:1672
SEHK:1672Biotechs

Assessing Ascletis Pharma (SEHK:1672) Valuation After Positive Acne Data And Denifanstat NDA Acceptance

Ascletis Pharma (SEHK:1672) is back in focus after reporting favorable long term safety data from its Phase III acne drug denifanstat and confirming that China’s regulator has accepted its New Drug Application. See our latest analysis for Ascletis Pharma. The acne data and NDA progress come on the back of an active few weeks across its GLP 1 and metabolic pipeline. The share price has moved accordingly, with a 30 day share price return of 19.79% and 90 day share price return of 40.67%, adding...